Lyuba Varticovski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4840130/publications.pdf

Version: 2024-02-01

66343 62596 7,208 81 42 80 citations h-index g-index papers 81 81 81 12271 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Endocrine disruptors of sex hormone activities. Molecular and Cellular Endocrinology, 2022, 539, 111415.	3.2	22
2	Mapping multiple endocrine disrupting activities in Virginia rivers using effect-based assays. Science of the Total Environment, 2021, 773, 145602.	8.0	7
3	Pilot study of global endocrine disrupting activity in Iowa public drinking water utilities using cell-based assays. Science of the Total Environment, 2020, 714, 136317.	8.0	15
4	Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environmental Health Perspectives, 2019, 127, 97009.	6.0	56
5	High Quality ATAC-Seq Data Recovered from Cryopreserved Breast Cell Lines and Tissue. Scientific Reports, 2019, 9, 516.	3.3	26
6	High fat diet-induced changes of mouse hepatic transcription and enhancer activity can be reversed by subsequent weight loss. Scientific Reports, 2017, 7, 40220.	3.3	62
7	Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. Toxicology, 2017, 385, 48-58.	4.2	24
8	Novel cell-based assay for detection of thyroid receptor beta-interacting environmental contaminants. Toxicology, 2016, 368-369, 69-79.	4.2	18
9	Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression. Science Translational Medicine, 2016, 8, 350ra104.	12.4	45
10	Genome-Wide Chromatin Landscape Transitions Identify Novel Pathways in Early Commitment to Osteoblast Differentiation. PLoS ONE, 2016, 11, e0148619.	2.5	15
11	Targeted H3R26 Deimination Specifically Facilitates Estrogen Receptor Binding by Modifying Nucleosome Structure. PLoS Genetics, 2014, 10, e1004613.	3.5	43
12	Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers. Cancer Research, 2013, 73, 184-194.	0.9	48
13	Clinicopathological Features and Outcomes of T- and NK-Cell Lymphomas in European Russia. Clinical Medicine Blood Disorders, 2012, 5, CMBD.S7804.	0.2	0
14	P6981, An Arylstibonic Acid, Is a Novel Low Nanomolar Inhibitor of cAMP Response Element-Binding Protein Binding to DNA. Molecular Pharmacology, 2012, 82, 814-823.	2.3	13
15	Dietary Energy Balance Modulates Epithelial-to-Mesenchymal Transition and Tumor Progression in Murine Claudin-Low and Basal-like Mammary Tumor Models. Cancer Prevention Research, 2012, 5, 930-942.	1.5	71
16	Prevalent Glucocorticoid and Androgen Activity in US Water Sources. Scientific Reports, 2012, 2, 937.	3.3	51
17	Complex dynamics of transcription regulation. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2012, 1819, 657-666.	1.9	44
18	Chromatin in time and space. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2012, 1819, 631.	1.9	9

#	Article	IF	CITATIONS
19	Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle, 2011, 10, 3119-3128.	2.6	45
20	Chaperone-Mediated Autophagy Is Required for Tumor Growth. Science Translational Medicine, 2011, 3, 109ra117.	12.4	205
21	The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells. European Journal of Cell Biology, 2010, 89, 564-573.	3.6	12
22	Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. British Journal of Cancer, 2010, 102, 1636-1644.	6.4	140
23	Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2195-2200.	7.1	122
24	Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. Clinical Cancer Research, 2010, 16, 1033-1041.	7.0	112
25	Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics. Journal of the National Cancer Institute, 2010, 102, 1637-1652.	6.3	241
26	Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8368-8373.	7.1	286
27	A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas. Nature Medicine, 2009, 15, 1369-1376.	30.7	149
28	microRNA expression in the biology, prognosis, and therapy of Waldenstr $ ilde{A}\P$ m macroglobulinemia. Blood, 2009, 113, 4391-4402.	1.4	113
29	Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. British Journal of Cancer, 2008, 98, 1515-1524.	6.4	106
30	Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity. BMC Cancer, 2008, 8, 176.	2.6	20
31	Harnessing genetically engineered mouse models for preclinical testing. Chemico-Biological Interactions, 2008, 171, 159-164.	4.0	15
32	Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1. Molecular Cancer, 2008, 7, 29.	19.2	33
33	Brca1 breast tumors contain distinct CD44+/CD24- and CD133+cells with cancer stem cell characteristics. Breast Cancer Research, 2008, 10, R10.	5.0	538
34	HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Molecular Cancer Therapeutics, 2008, 7, 1985-1992.	4.1	70
35	Obesity Accelerates Mouse Mammary Tumor Growth in the Absence of Ovarian Hormones. Nutrition and Cancer, 2008, 60, 534-541.	2.0	81
36	The Chaperone-Mediated Autophagy Receptor Organizes in Dynamic Protein Complexes at the Lysosomal Membrane. Molecular and Cellular Biology, 2008, 28, 5747-5763.	2.3	435

#	Article	IF	Citations
37	Lung Cancer Stem Cells. Disease Markers, 2008, 24, 257-266.	1.3	29
38	The Obesity-Cancer Link: Lessons Learned from a Fatless Mouse: Figure 1 Cancer Research, 2007, 67, 2391-2393.	0.9	105
39	Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models. Clinical Cancer Research, 2007, 13, 2168-2177.	7.0	44
40	Inhibitor of Growth 4 Suppresses Cell Spreading and Cell Migration by Interacting with a Novel Binding Partner, Liprin $\hat{l}\pm 1$. Cancer Research, 2007, 67, 2552-2558.	0.9	113
41	Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance. Cancer Research, 2007, 67, 10397-10405.	0.9	118
42	Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines. Clinical Cancer Research, 2006, 12, 6547-6556.	7.0	35
43	Accelerated Tumor Formation in a Fatless Mouse with Type 2 Diabetes and Inflammation. Cancer Research, 2006, 66, 5469-5476.	0.9	82
44	Bisindenoisoquinoline Bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA Intercalator and Topoisomerase Inhibitor with Antitumor Activity. Molecular Pharmacology, 2006, 70, 1109-1120.	2.3	38
45	The p53 Tumor Suppressor Network Is a Key Responder to Microenvironmental Components of Chronic Inflammatory Stress. Cancer Research, 2005, 65, 10255-10264.	0.9	93
46	A Direct Binding Site for Grb2 Contributes to Transformation and Leukemogenesis by the Tel-Abl (ETV6-Abl) Tyrosine Kinase. Molecular and Cellular Biology, 2004, 24, 4685-4695.	2.3	42
47	The Knockout Mouse Project. Nature Genetics, 2004, 36, 921-924.	21.4	556
48	Opposing effect of angiopoietin-1 on VEGF-mediated disruption of endothelial cell-cell interactions requires activation of PKC?. Journal of Cellular Physiology, 2004, 198, 53-61.	4.1	52
49	Identification of carboxypeptidase E and \hat{I}^3 -glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Human Pathology, 2004, 35, 1196-1209.	2.0	69
50	Mechanisms by which cAMP increases bile acid secretion in rat liver and canalicular membrane vesicles. American Journal of Physiology - Renal Physiology, 2003, 285, G316-G324.	3.4	42
51	Mechanism by which cAMP activates PI3-kinase and increases bile acid secretion in WIF-B9 cells. American Journal of Physiology - Cell Physiology, 2002, 283, C1655-C1666.	4.6	33
52	NERF2, a member of the Ets family of transcription factors, is increased in response to hypoxia and angiopoietin-1: A potential mechanism for Tie2 regulation during hypoxia. Journal of Cellular Biochemistry, 2002, 85, 505-515.	2.6	37
53	Dynamin inhibits phosphatidylinositol 3-kinase in hematopoietic cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2001, 1538, 10-19.	4.1	9
54	The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood, 2001, 97, 4-13.	1.4	93

#	Article	lF	CITATIONS
55	Mitogenic signaling by cyclic adenosine monophosphate in chromaffin cells involves phosphatidylinositol 3-kinase activation. Journal of Cellular Biochemistry, 2001, 81, 89-98.	2.6	7
56	Water-soluble HPMA copolymer–wortmannin conjugate retains phosphoinositide 3-kinase inhibitory activity in vitro and in vivo. Journal of Controlled Release, 2001, 74, 275-281.	9.9	29
57	Probing Fibroblast Growth Factor Dimerization and Role of Heparin-like Glycosaminoglycans in Modulating Dimerization and Signaling. Journal of Biological Chemistry, 2001, 276, 23421-23429.	3.4	37
58	Inactivation of wild-type BCR/ABL tyrosine kinase in hematopoietic cells by mild hyperthermia. Leukemia, 2000, 14, 845-852.	7.2	3
59	Role of PI 3–Kinase in Angiopoietin-1-Mediated Migration and Attachment-Dependent Survival of Endothelial Cells. Experimental Cell Research, 2000, 255, 133.	2.6	1
60	Expression of Tie1 and Tie2 Proteins during Reendothelialization in Balloon-Injured Rat Carotid Artery. Journal of Vascular Research, 1999, 36, 272-281.	1.4	12
61	Phosphoinositide 3-kinase lipid products regulate ATP-dependent transport by sister of P-glycoprotein and multidrug resistance associated protein 2 in bile canalicular membrane vesicles. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5814-5819.	7.1	103
62	Role of PI 3-Kinase in Angiopoietin-1-Mediated Migration and Attachment-Dependent Survival of Endothelial Cells. Experimental Cell Research, 1999, 253, 663-672.	2.6	130
63	The Role of Phosphoinositide 3-Kinase in Taurocholate-induced Trafficking of ATP-dependent Canalicular Transporters in Rat Liver. Journal of Biological Chemistry, 1998, 273, 26638-26644.	3.4	123
64	Tyrosine Phosphorylation of the CD3-ε Subunit of the T Cell Antigen Receptor Mediates Enhanced Association with Phosphatidylinositol 3-Kinase in Jurkat T Cells. Journal of Biological Chemistry, 1997, 272, 25310-25318.	3.4	45
65	Divergence in Signal Transduction Pathways of Platelet-derived Growth Factor (PDGF) and Epidermal Growth Factor (EGF) Receptors. Journal of Biological Chemistry, 1997, 272, 10777-10783.	3.4	108
66	Evidence for phosphatidylinositol 3-kinase-dependent T cell antigen receptor (TCR) signal transduction. Molecular Immunology, 1997, 34, 221-226.	2.2	14
67	Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase. Oncogene, 1997, 14, 2217-2228.	5.9	54
68	Effect of a xanthine analog on human hepatocellular carcinoma cells (Alexander) in culture and in xenografts in SCID mice. Hepatology, 1997, 26, 1195-1202.	7.3	4
69	Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression Journal of Clinical Investigation, 1996, 97, 469-476.	8.2	310
70	Phorbol ester treatment inhibits phosphatidylinositol 3-kinase activation by, and association with, CD28, a T-lymphocyte surface receptor Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 8808-8812.	7.1	29
71	Hypoxia Induces Vascular Endothelial Growth Factor in Cultured Human Endothelial Cells. Journal of Biological Chemistry, 1995, 270, 31189-31195.	3.4	413
72	Phosphatidylinositol 3-Kinase Activity in Murine Erythroleukemia Cells during DMSO-Induced Differentiation. Experimental Cell Research, 1995, 219, 454-460.	2.6	16

#	Article	IF	CITATIONS
73	Naturally occurring ether-linked phosphatidylcholine activates phosphatidylinositol 3-kinase and stimulates cell growth. Journal of Cellular Biochemistry, 1994, 55, 146-153.	2.6	8
74	Serine-Rich Region of the IL-2 Receptor \hat{l}^2 -Chain Is Required for Activation of Phosphatidylinositol 3-Kinase. Cellular Immunology, 1994, 156, 378-388.	3.0	10
75	Role of PI 3-kinase in mitogenesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1994, 1226, 1-11.	3.8	83
76	The colony stimulating factor-1 receptor associates with and activates phosphatidylinositol-3 kinase. Nature, 1989, 342, 699-702.	27.8	354
77	Location of sites in human lipocortin I that are phosphorylated by protein tyrosine kinases and protein kinases A and C. Biochemistry, 1988, 27, 3682-3690.	2.5	101
78	Paradoxical stimulation of both lipocortin and prostaglandin production in human amnion cells by dexamethasone. Biochemical and Biophysical Research Communications, 1988, 151, 137-141.	2.1	64
79	Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells. Science, 1988, 239, 628-631.	12.6	254
80	T-Lymphocyte Subpopulations in Homosexual Men. New England Journal of Medicine, 1983, 308, 398-399.	27.0	4
81	Biosynthesis of porphyrin precursors: Kinetic studies on mammalian l-alanine: γ,δ-Dioxovaleric acid aminotransferase. International Journal of Biochemistry & Cell Biology, 1980, 12, 739-744.	0.5	10